Cargando…
Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy
BACKGROUND AND PURPOSE: Amyloid myopathy is a rare and severe manifestation of systemic light chain (AL) amyloidosis. Early diagnosis and staging are mandatory for optimal therapy, given the rapid progression of muscle weakness. Despite the efficacy of bortezomib‐based treatment regimens, there is a...
Autores principales: | Chitimus, Diana Maria, Berling, Edouard, Garderet, Laurent, Venturelli, Nadia, Malfatti, Edoardo, Authier, François Jérôme, Nicolas, Guillaume, Laforêt, Pascal, Lefeuvre, Claire |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098764/ https://www.ncbi.nlm.nih.gov/pubmed/36403110 http://dx.doi.org/10.1111/ene.15640 |
Ejemplares similares
-
Safety and tolerability of SARS‐Cov‐2 vaccination in patients with myasthenia gravis: A multicenter experience
por: Farina, Antonio, et al.
Publicado: (2022) -
Short‐term and sustained clinical response following thymectomy in patients with myasthenia gravis
por: Rath, Jakob, et al.
Publicado: (2022) -
Clinico‐genetic spectrum of limb‐girdle muscular weakness in Austria: A multicentre cohort study
por: Krenn, Martin, et al.
Publicado: (2022) -
Shedding light on motor premanifest myotonic dystrophy type 1: A molecular, muscular and central nervous system follow‐up study
por: Garmendia, Joana, et al.
Publicado: (2022) -
Inflammatory myopathies: an update for neurologists
por: Silva, André Macedo Serafim, et al.
Publicado: (2022)